Abstract: The present disclosure relates to a ready-to-administer (RTA), intravenous (IV) bag presentation for hydromorphone. In particular, the present disclosure relates to terminally sterilized liquid formulations comprising hydromorphone hydrochloride in sodium chloride packaged in an RTA IV bag. The present disclosure also relates to methods of treating patients by administration of such formulations and RTA IV bags containing such formulations.

Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.

Abstract: A method for real-time, high-density physiological data collection includes automatically measuring, by a wearable device, one or more physiological parameters during each of a plurality of measurement periods, and upon conclusion of a measurement period, for each of the plurality of measurement periods, automatically transmitting by the wearable device data representative of the physiological parameters measured during that measurement period, to a server, the server configured to develop a baseline profile based on the data transmitted by the wearable device for the plurality of measurement periods. The measurement periods may extend through a plurality of consecutive days, and each of the consecutive days may include multiple measurement periods. At least some of the physiological parameters are measured by non-invasively detecting one or more analytes in blood circulating in subsurface vasculature proximate to the wearable device.

Abstract: High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Abstract: A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal.

Abstract: High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Abstract: High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.

Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.

Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.

Abstract: High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Abstract: High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Abstract: A wearable device includes a detector configured to detect a response signal transmitted from a portion of subsurface vasculature, the response signal being related to binding of a clinically-relevant analyte to functionalized particles present in a lumen of the subsurface vasculature. Program instructions stored in a computer readable medium of the device, and executable by a processor, may cause the device to determine a concentration of the clinically-relevant analyte based on the response signal detected by the detector; determine whether a medical condition is indicated based on at least the concentration of the clinically-relevant analyte; and, in response to a determination that the medical condition is indicated, transmit data representative of the medical condition via the communication interface.

Abstract: A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal.

Abstract: A method for real-time, high-density physiological data collection includes automatically measuring, by a wearable device, one or more physiological parameters during each of a plurality of measurement periods, and upon conclusion of a measurement period, for each of the plurality of measurement periods, automatically transmitting by the wearable device data representative of the physiological parameters measured during that measurement period, to a server, the server configured to develop a baseline profile based on the data transmitted by the wearable device for the plurality of measurement periods. The measurement periods may extend through a plurality of consecutive days, and each of the consecutive days may include multiple measurement periods. At least some of the physiological parameters are measured by non-invasively detecting one or more analytes in blood circulating in subsurface vasculature proximate to the wearable device.

Abstract: A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal.

Abstract: A method for real-time, high-density physiological data collection includes automatically measuring, by a wearable device, one or more physiological parameters during each of a plurality of measurement periods, and upon conclusion of a measurement period, for each of the plurality of measurement periods, automatically transmitting by the wearable device data representative of the physiological parameters measured during that measurement period, to a server, the server configured to develop a baseline profile based on the data transmitted by the wearable device for the plurality of measurement periods. The measurement periods may extend through a plurality of consecutive days, and each of the consecutive days may include multiple measurement periods. At least some of the physiological parameters are measured by non-invasively detecting one or more analytes in blood circulating in subsurface vasculature proximate to the wearable device.

Abstract: High-throughput hyperspectral imaging systems are provided. According to an aspect of the invention, a system includes an excitation light source; an objective that is configured to image excitation light onto the sample, such that the excitation light causes the sample to emit fluorescence light; a channel separator that is configured to separate the fluorescence light into a plurality of spatially dispersed spectral channels; and a sensor. The excitation light source includes a light source and a plurality of lenslet arrays. Each of the lenslet arrays is configured to receive light from the light source and to generate a pattern of light, and the patterns of light generated by the lenslet arrays are combined to form the excitation light. The objective is configured to simultaneously image each of the patterns of light to form a plurality of parallel lines or an array of circular spots at different depths of the sample.

Abstract: Embodiments described herein may help to provide medical support via a fleet of unmanned aerial vehicles (UAVs). An illustrative UAV may include a housing, a payload, a line-deployment mechanism coupled to the housing and a line, and a payload-release mechanism that couples the line to the payload, wherein the payload-release mechanism is configured to release the payload from the line. The UAV may further include a control system configured to determine that the UAV is located at or near a delivery location and responsively: operate the line-deployment mechanism according to a variable deployment-rate profile to lower the payload to or near to the ground, determine that the payload is touching or is within a threshold distance from the ground, and responsively operate the payload-release mechanism to release the payload from the line.

Abstract: Embodiments described herein may help to provide medical support via a fleet of unmanned aerial vehicles (UAVs). An illustrative UAV may include a housing, a payload, a line-deployment mechanism coupled to the housing and a line, and a payload-release mechanism that couples the line to the payload, wherein the payload-release mechanism is configured to release the payload from the line. The UAV may further include a control system configured to determine that the UAV is located at or near a delivery location and responsively: operate the line-deployment mechanism according to a variable deployment-rate profile to lower the payload to or near to the ground, determine that the payload is touching or is within a threshold distance from the ground, and responsively operate the payload-release mechanism to release the payload from the line.